applied sciences

MDPI

Supplementary Materials



Supplementary Figure S1. A 22-year-old HBeAg positive female rapidly developed liver cirrhosis that spontaneously resolved 34 years later. (**a**) The clinical course and timing of four liver histology studies are shown; three biopsies were performed as part of a clinical trial for Ara-A during a severe ALT flare-up, and the last biopsy was collected during a segmentectomy performed for a progressively enlarged angiomyolipoma. (**b**) The initial silver stained histology section revealed relatively normal reticulum architecture. (**c**) Four months later, severe bridging fibrosis was noted. (**d**) Well-recognized cirrhotic nodules were noted seven months after the initial biopsy. (**e**) Thirty-four years after HBeAg seroconversion, hematoxylin and eosin staining of the non-tumor portion of the liver biopsy revealed a nearly normal liver with an METAVIR fibrosis score of F1.

Supplementary Table S1a. ARFI cutoff values in different fibrosis grades.

Study	No.	Etiology	Cut Off	AUROC Curve
Ye 2011[1]	264	CHB	F ≥3: 1.69; F4: 1.88	F ≥3: 0.99; F4: 0.97
Friedrich-Rust M 2013[2]	112	CHB	F ≥2: 1.39	F ≥2: 0.73
Liu 2015[3]	108	CHB	F ≥2: 1.27; F4: 1.65	F ≥2: 0.91; F4: 0.96
Zhang 2015#[4]	180	CHB	S≥2: 1.46; S≥3: 1.59; S4: 1.75	S≥2: 0.76; S≥3: 0.85; S4: 0.82
Park 2016[5]	105	CHB	F≥2: 1.31; F ≥3: 1.81; F4: 1.98	F ≥2: 0.81; F ≥3: 0.85; F4: 0.75
Lupsor 2009[6]	112	CHC	F ≥2: 1.34; F ≥3: 1.61; F4: 2.0	F ≥2: 0.85; F ≥3: 0.87; F4: 0.91
Rizzo 2011[7]	139	CHC	F ≥2: 1.30; F ≥3: 1.70; F4: 2.0	F ≥2: 0.86; F ≥3: 0.94; F4: 0.89
Sporea 2011[8]	274	CHC	F≥2: 1.21; F ≥3: 1.58; F4: 1.82	F≥2: 0.89; F ≥3: 0.91; F4: 0.94
Sporea 2012[9]				
European	453	CHC	F ≥2: 1.21; F =4:1.74	F ≥2: 0.86; F =4:0.89
Asian	461	CHC	F ≥2: 1.32; F =4:1.55	F ≥2: 0.74; F =4:0.74
Yamada 2014[10]	124	CHC	F ≥2: 1.26; F ≥3:1.46	F ≥2: 0.89; F ≥3: 0.94
Li 2014[11]	128	CHC	F ≥2: 1.53; F ≥3: 1.79; F4: 1.789	F ≥2: 0.76; F ≥3: 0.9; F4: 0.79
Nishikawa 2014[12]	108	CHC	F ≥2: 1.28; F ≥3: 1.44; F4: 1.73	F ≥2: 0.91; F ≥3: 0.87; F4: 0.89
Takaki 2014[13]	176	CHC	F ≥2: 1.25; F ≥3: 1.6; F4: 1.78	F ≥2: 0.77; F ≥3: 0.86; F4: 0.92
Chen 2015[14]	137	CHC	F ≥2: 1.59; F ≥3: 1.73; F4: 1.96	F ≥2: 0.93; F ≥3: 0.9; F4: 0.86
Cassinotto 2013⊙[15]	321	NASH	F ≥2: 1.38; F ≥3: 1.51; F4: 1.61	F ≥2: 1.38 F ≥3: 1.57; F4: 1.61
Cassinotto 2016⊕[16]	291	NAFLD	F ≥2: 1.13; F ≥3: 1.45; F4: 1.88	F ≥2: 0.77; F ≥3: 0.84; F4: 0.84
Joo 2017⊕[17]	315	NAFLD	F ≥2: 1.43; F ≥3: 1.29; F4: 1.75	F ≥2: 0.93; F ≥3: 0.81; F4: 0.76

Histological score: # Scheuer, ⊕: Kleiner, ⊙: Brunt, other: Metavir.

Supplementary Table S1b. Transient elastography Cutoff values in different fibrosis grades.

Study	No	Etiology	Cut Off	AUROC Curve
Marcellin 2009[18]	173	CHB	F≥2: 7.2; F≥3: 8.1; F=4: 11	F≥2: 0.81; F≥3: 0.93; F=4: 0.93
Chan 2009* [19]	161	CHB	F ≥ 3: 8.4; F = 4: 9	F ≥ 3: 0.87; F = 4: 0.93
Chon2012[20]	2,772	CHB	F ≥ 2: 7.9; F ≥ 3: 8.8; F = 4: 11.7	F ≥ 2: 0.86; F ≥ 3: 0.89; F = 4: 0.93
Liu 2015*[3]	108	CHB	F≥2: 6.6; F4: 9.47	F≥2: 0.87; F4: 0.96
Zhang 2015 #[4]	180	CHB	S≥2: 7.5; S≥3: 9.8; S=4: 10.6	S≥2: 0.81; S≥3: 0.85; S=4: 0.8
Cai 2017@ [21]	488	CHB	S0-2/S3-6: 7.81; S0-3/S4-6: 10.04	S0-2/S3-6: 0.9; S0-3/S4-6: 0.93
			S0-2/S3-6: 8.25; S0-3/S4-6: 10.99	S0-2/S3-6:0.83; S0-3/S4-6: 0.93
Castera 2005*[22]	183	CHC	F≥2: 7.1; F≥3: 9.5; F=4: 12.5	F≥2: 0.83; F≥3: 0.90; F=4: 0.95
Ziol 2005* [23]	327	CHC	F≥2: 8.8; F≥3: 9.6; F=4: 14.6	F≥2: 0.79; F≥3: 0.91; F=4: 0.97
Lupsor 2009*[6]	112	CHC	F ≥ 2: 8.1; F ≥ 3: 9.6; F = 4:13.1	F ≥ 2: 0.94; F ≥ 3: 0.93; F = 4: 0.95
Degos 2010*[24]	913	CHC	F≥2: 5.2; F=4: 12.9	F≥2: 0.75; F=4: 0.9
Rizzo 2011*[7]	139	CHC	F ≥ 2: 6.5; F ≥ 3: 8.8; F = 4: 11	F ≥ 2: 0.78; F ≥ 3: 0.83; F = 4: 0.8
Zarski2012*[25]	382	CHC	F≥2:5.2; F=4: 12.9	F≥2:0.82; F=4: 0.93
Cassinotto⊕2016[16]	291	NAFLD	F ≥ 2: 8.4; F ≥ 3: 12; F = 4: 23.6	F ≥ 2: 0.82; F ≥ 3: 0.86; F = 4:0.87
Imajo 2016⊙[26]	142	NAFLD	F≥2: 11; F≥3: 11.4; F=4: 14	F≥2: 0.82; F≥3: 0.88; F=4: 0.92
Wong 2010⊕[27]	246	NAFLD	F≥2: 7; F≥3: 8.7; F=4: 10.3	F≥2: 0.84; F≥3: 0.93; F=4: 0.95

Histological score: #: Scheuer @: Ishak, ⊕: Kleiner, ⊙: Brunt, other: Metavir.

Supplementary References

1. Ye XP, Ran HT, Cheng J, et al. Liver and spleen stiffness measured by acoustic radiation force impulse elastography for noninvasive assessment of liver fibrosis and esophageal varices in patients with chronic hepatitis B. *J Ultrasound Med* **2012**, *31*, 1245–1253.
2. Friedrich-Rust M, Buggisch P, de Knegt RJ, et al. Acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in chronic hepatitis B. *Journal of viral hepatitis*. **2013**, *20*, 240–247.
3. Liu Y, Dong CF, Yang G, et al. Optimal linear combination of ARFI, transient elastography and APRI for the assessment of fibrosis in chronic hepatitis B. *Liver international: official journal of the International Association for the Study of the Liver.* **2015**, *35*, 816–825.
4. Zhang D, Chen M, Wang R, et al. Comparison of acoustic radiation force impulse imaging and transient elastography for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. *Ultrasound Med Biol* **2015**, *41*, 7–14.
5. Park MS, Kim SW, Yoon KT, et al. Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. *Gut and liver*. **2016**, *10*, 275–282.
6. Lupsor M, Badea R, Stefanescu H, et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary Results. *J Gastrointestin Liver Dis* **2009**, *18*, 303–310.
7. Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. *Am J Gastroenterol* **2011**, *106*, 2112–2120.
8. Sporea I, Sirli R, Bota S, et al. Is ARFI elastography reliable for predicting fibrosis severity in chronic HCV hepatitis? *World J Radiol* **2011**, *3*, 188–193.
9. Sporea I, Bota S, Peck-Radosavljevic M, et al. Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. *Eur J Radiol*. **2012**, *81*, 4112–4118.
10. Yamada R, Hiramatsu N, Oze T, et al. Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients. *J Med Virol*. **2014**, *86*, 241–247.
11. Li SM, Li GX, Fu DM, Wang Y, Dang LQ. Liver fibrosis evaluation by ARFI and APRI in chronic hepatitis C. *World J Gastroenterol* **2014**, *20*, 9528–9533.
12. Nishikawa T, Hashimoto S, Kawabe N, et al. Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C. *World J Gastroenterol* **2014**, *20*, 1289–1297.
13. Takaki S, Kawakami Y, Miyaki D, et al. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. *Hepatol Res* **2014**, *44*, 280–287.
14. Chen SH, Peng CY, Lai HC, et al. Head-to-Head Comparison between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Quantification in Chronic Hepatitis C. *PLoS One* **2015**, *10*, e0140554.
15. Cassinotto C, Lapuyade B, Ait-Ali A, et al. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. *Radiology* **2013**, *269*, 283–292.
16. Cassinotto C, Boursier J, de Ledinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. *Hepatology (Baltimore, Md)*. **2016**, *63*, 1817–1827.
17. Joo SK, Kim W, Kim D, et al. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. *Liver international: official journal of the International Association for the Study of the Liver.* **2018**, *38*, 331–341.
18. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. *Liver international: official journal of the International Association for the Study of the Liver.* **2009**, *29*, 242–247.
19. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. *Journal of viral hepatitis.* **2009**, *16*, 36–44.
20. Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. *PloS one* **2012**, *7*, e44930.

21. Cai YJ, Dong JJ, Wang XD, et al. A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B. *Journal of viral hepatitis.* **2017**, *24*, 1005–1015.
22. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* **2005**, *128*, 343–350.
23. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology.* **2005**, *41*, 48–54.
24. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). *Journal of hepatology.* **2010**, *53*, 1013–1021.
25. Zarski JP, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. *Journal of hepatology.* **2012**, *56*, 55–62.
26. Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, Fujita K, Yoneda M, Taguri M, Hyogo H, Sumida Y, Ono M, Eguchi Y, Inoue T, Yamanaka T, Wada K, Saito S, Nakajima A. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. *Gastroenterology* **2016**, *150*, 626.e7–637.e7
27. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, de Lédinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* **2010**, *51*, 454–462.